Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Director | June 29, 2026 | July 01, 2026 |
| Pelthos Therapeutics Inc.PTHS · Entity 6798 | Director | October 02, 2026 | October 06, 2026 |
| Savara IncSVRA · Entity 4900 | Director · CHIEF EXECUTIVE OFFICER | December 14, 2025 | December 16, 2025 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Director · President & CEO | February 20, 2019 | February 22, 2019 |
| Zyla Life SciencesZCOR · Entity 148990 | Director | May 20, 2020 | May 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $154.84 · Expires 2036-06-29 | Direct | 6,000 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 6,000 · Balance 6,000 F1: The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
Pelthos Therapeutics Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,578 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 786 · Balance 13,578 F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
Savara Inc
Report date December 14, 2025 · Filed December 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,188,050 |
Ending reported balance
After 2025-12-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-14 · Tax withholding · Disposed 195,705 · Balance 1,317,045 F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Row 2 · 2025-12-16 · Gift · Disposed 128,995 · Balance 1,188,050 F2: On December 16, 2025, the reporting person transferred 128,995 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the reporting person disclaims beneficial ownership of the shares held by the trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units.
F2: On December 16, 2025, the reporting person transferred 128,995 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the reporting person disclaims beneficial ownership of the shares held by the trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any.
Strongbridge Biopharma plc
Report date February 20, 2019 · Filed February 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 72,608 |
Reported balance
After 2019-02-20 transaction · row 1
1 source rowRow 1 · 2019-02-20 · Grant · Acquired 50,000 · Balance 72,608 F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2029-02-20 | Direct | 400,000 |
Reported balance
After 2019-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-20 · Grant · Acquired 400,000 · Balance 400,000 F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date.
Zyla Life Sciences
Report date May 20, 2020 · Filed May 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Disposition to issuer · Disposed 26,953 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time. F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time.
F2: Includes unvested time-based restricted stock units representing a contingent right to receive 26,953 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 10,491 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 · Expires 2033-08-15 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 9,063 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 21:53 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 786 | $21.00 | $16,506.00 |
DisclosureSEC source: 0001919246-26-000129 · wk-form4_1791323618.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,578 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 94 | $27.36 | $2,571.88 |
DisclosureSEC source: 0001919246-26-000101 · wk-form4_1783458216.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,364 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 21:03 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 692 | $26.00 | $17,989.16 |
DisclosureSEC source: 0001919246-26-000101 · wk-form4_1783458216.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,458 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $154.84 | $0.00 |
DisclosureSEC source: 0001104659-26-079865 · tm2619349-2_4seq1.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-29 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:44 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 9,063 | Not disclosed Strike: $4.60 | Not disclosed |
DisclosureSEC source: 0001573429-26-000001 · form4-05182026_080531.xml · derivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,063 shares Expires 2033-08-15 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:44 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 10,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001573429-26-000001 · form4-05182026_080531.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:02 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 371 | $21.36 | $7,925.60 |
DisclosureSEC source: 0001919246-26-000053 · wk-form4_1775509361.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,150 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 21:02 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | SaleCommon Stock | 415 | $20.52 | $8,513.89 |
DisclosureSEC source: 0001919246-26-000053 · wk-form4_1775509361.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,521 F1 · kind: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 16, 2025 Filed Dec 16, 2025 22:28 UTC | Savara Inc SVRA · Entity 4900 | GiftCommon Stock | 128,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-321185 · ownership.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,188,050 F2 · shares: On December 16, 2025, the reporting person transferred 128,995 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the reporting person disclaims beneficial ownership of the shares held by the trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any. Read SEC document |
| December 14, 2025 Filed Dec 16, 2025 22:28 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 195,705 | $6.92 | $1,354,278.60 |
DisclosureSEC source: 0001193125-25-321185 · ownership.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,317,045 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 22:44 UTC | Savara Inc SVRA · Entity 4900 | GiftCommon Stock | 23,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-316295 · ownership.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,512,750 F1 · shares: The reporting person made a bona fide gift to The Pennington School. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 22:01 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GiftCommon Stock | 9,542 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001884 · ownership.xml · nonDerivative · entry 3 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074 F2 · shares: On December 10, 2025, the Reporting Person transferred 9,542 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The Reporting Person is not a trustee and does not retain investment or voting control over the shares. Following the gift, the Reporting Person disclaims beneficial ownership of the shares held by the Trust and reports beneficial ownership herein only to the extent of any pecuniary interest, if any. Read SEC document |
| October 02, 2025 Filed Dec 12, 2025 22:01 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | Exercise / conversionRestricted Stock Units · Derivative | 2,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001884 · ownership.xml · derivative · entry 5 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,862 Underlying: Common Stock · 2,123 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer's Common Stock. F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.exercise_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.expiration_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.underlying_shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| October 02, 2025 Filed Dec 12, 2025 22:01 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | Exercise / conversionCommon Stock | 2,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001884 · ownership.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:45 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantStock Option · Derivative | 77,640 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001753926-25-001107 · ownership.xml · derivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,640 Underlying: Common Stock · 77,640 shares Expires 2035-07-02 F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 77,640 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| July 02, 2025 Filed Jul 8, 2025 01:45 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantRestricted Stock Units · Derivative | 25,478 | Not disclosed Strike: $13.50 | Not disclosed |
DisclosureSEC source: 0001753926-25-001107 · ownership.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,478 Underlying: Common Stock · 25,478 shares Expires 2035-07-02 F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 25,478 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2025, and in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| July 02, 2025 Filed Dec 12, 2025 22:01 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | Exercise / conversionRestricted Stock Units · Derivative | 8,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001884 · ownership.xml · derivative · entry 4 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,985 Underlying: Common Stock · 8,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer's Common Stock. F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.exercise_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.expiration_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · derivative.underlying_shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| July 02, 2025 Filed Dec 12, 2025 22:01 UTC | Pelthos Therapeutics Inc. PTHS · Entity 6798 | Exercise / conversionCommon Stock | 8,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-001884 · ownership.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years. Read SEC document |
| July 02, 2025 Filed Apr 1, 2026 21:42 UTC Amendment | Pelthos Therapeutics Inc. PTHS · Entity 6798 | GrantCommon Stock | 25,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001919246-26-000042 · wk-form4a_1775079764.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,478 F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 23:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016358 · form4-06092025_110609.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,491 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 5, 2025 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. The Reporting Person previously elected to defer receipt of the shares of Common Stock underlying RSUs upon vesting. In accordance with the Reporting Person's deferral election the vested shares will be delivered to the Reporting Person when the Reporting Person ceases to provide services to the Issuer or upon a change of control of the Issuer. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 23:24 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,937 | $0.00 Strike: $46.31 | $0.00 |
DisclosureSEC source: 0001415889-25-009298 · form4-03312025_110330.xml · derivative · entry 3 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,063 Underlying: Common Stock · 5,937 shares Expires 2033-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the Option shall vest on September 15, 2023 and each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 23:24 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 5,937 | $71.55 | $424,797.10 |
DisclosureSEC source: 0001415889-25-009298 · form4-03312025_110330.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 F2 · price: This transaction was executed in multiple trades at prices ranging from $71.54 to $71.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F1 · balance_after: Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| March 28, 2025 Filed Mar 31, 2025 23:24 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionCommon Stock | 5,937 | $4.60 | $27,310.20 |
DisclosureSEC source: 0001415889-25-009298 · form4-03312025_110330.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| December 16, 2024 Filed Dec 16, 2024 22:56 UTC | Savara Inc SVRA · Entity 4900 | SaleCommon Stock | 54,702 | $3.31 | $180,828.40 |
DisclosureSEC source: 0000950170-24-136782 · ownership.xml · nonDerivative · entry 3 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,536,379 F2 · shares: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F3 · price: The price is a weighted average sales price. The sale prices ranged from $3.28 to $3.34. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 22:56 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 92,593 | $3.21 | $297,223.53 |
DisclosureSEC source: 0000950170-24-136782 · ownership.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,591,081 Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:56 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 900,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000950170-24-136782 · ownership.xml · derivative · entry 4 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2034-12-12 F4 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 12, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 22:56 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-136782 · ownership.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683,674 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 12, 2026, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 06, 2024 Filed Jun 11, 2024 00:50 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016310 · form4-06112024_120618.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. The Reporting Person previously elected to defer receipt of the shares of Common Stock underlying RSUs upon vesting. In accordance with the Reporting Person's deferral election the vested shares will be delivered to the Reporting Person when the Reporting Person ceases to provide services to the Issuer or upon a change of control of the Issuer. F1 · balance_after: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. The Reporting Person previously elected to defer receipt of the shares of Common Stock underlying RSUs upon vesting. In accordance with the Reporting Person's deferral election the vested shares will be delivered to the Reporting Person when the Reporting Person ceases to provide services to the Issuer or upon a change of control of the Issuer. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:35 UTC | Savara Inc SVRA · Entity 4900 | GiftCommon Stock | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-060009 · doc4.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,283,674 F3 · shares: The reporting person made a bona fide gift to The Pennington School. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:35 UTC | Savara Inc SVRA · Entity 4900 | SaleCommon Stock | 84,000 | $4.71 | $395,900.40 |
DisclosureSEC source: 0001209191-23-060009 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,302,674 F1 · shares: Represents shares sold to satisfy tax liability upon the vesting of restricted stock units. F2 · price: The price is a weighted average sales price. The sale prices ranged from $4.70 to $4.795. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:46 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-23-058850 · doc4.xml · derivative · entry 3 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2033-12-14 F3 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:46 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058850 · doc4.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,386,674 F2 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2025, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 14, 2023 Filed Dec 15, 2023 22:46 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 109,680 | $4.45 | $488,076.00 |
DisclosureSEC source: 0001209191-23-058850 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,674 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 20:13 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001209191-23-046006 · doc4.xml · derivative · entry 1 Pauls Matthew · CIK 0001573429 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-08-15 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the Option shall vest on September 15, 2023 and each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider through each such date. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:06 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001209191-22-061411 · doc4.xml · derivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-12-13 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 13, 2022, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:06 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 325,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061411 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046,354 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 13, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:10 UTC | Savara Inc SVRA · Entity 4900 | Tax withholdingCommon Stock | 62,318 | $1.24 | $77,274.32 |
DisclosureSEC source: 0001209191-22-000131 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721,354 F1 · shares: Represents shares withheld by the Issuer in connection with the reporting person's net share settlement to satisfy tax liability based upon the vesting of previously awarded restricted stock units. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 23:31 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-21-069586 · doc4.xml · derivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-12-14 F2 · derivative.exercise_date: The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 14, 2021, subject to the reporting person's continued service with the Issuer. Read SEC document |
| December 14, 2021 Filed Dec 14, 2021 23:31 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069586 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,672 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 08, 2021 Filed Dec 8, 2021 19:41 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 6,500 | $1.06 | $6,889.35 |
DisclosureSEC source: 0001209191-21-068494 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,672 Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 17:28 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 10,000 | $1.10 | $10,954.00 |
DisclosureSEC source: 0001209191-21-067432 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,172 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.0925 to $1.10. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:42 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 2,150 | $1.07 | $2,289.75 |
DisclosureSEC source: 0001209191-21-066036 · doc4.xml · nonDerivative · entry 3 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,172 Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 16:42 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 10,000 | $1.11 | $11,100.00 |
DisclosureSEC source: 0001209191-21-066036 · doc4.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,022 Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 16:42 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 10,000 | $1.10 | $11,000.00 |
DisclosureSEC source: 0001209191-21-066036 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,022 Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 20:03 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 11,900 | $1.19 | $14,165.76 |
DisclosureSEC source: 0001209191-21-052200 · doc4.xml · nonDerivative · entry 2 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,022 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.175 to $1.205. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 20:03 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 15,000 | $1.18 | $17,700.00 |
DisclosureSEC source: 0001209191-21-052200 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,122 Read SEC document |
| May 21, 2021 Filed May 24, 2021 12:10 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 10,000 | $1.63 | $16,298.00 |
DisclosureSEC source: 0001209191-21-035163 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,122 F1 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.625 to $1.63. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 19, 2021 18:46 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 27,400 | $1.82 | $49,870.74 |
DisclosureSEC source: 0001209191-21-027226 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,122 F1 · shares: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.79 to $1.88. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 23, 2021 01:47 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 24,100 | $2.07 | $49,937.61 |
DisclosureSEC source: 0001209191-21-022485 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,722 F1 · shares: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $2.04 to $2.11. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 14:48 UTC | Savara Inc SVRA · Entity 4900 | PurchaseCommon Stock | 28,700 | $1.74 | $50,038.45 |
DisclosureSEC source: 0001209191-21-013062 · doc4.xml · nonDerivative · entry 1 Pauls Matthew · CIK 0001573429 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,622 F1 · shares: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020. F2 · price: The price is a weighted average purchase price. The purchase prices ranged from $1.73 to $1.80. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.